Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial

Lü, Zhihao; Zhang, Yanqiao; Fan, Qingxia; Pan, Yueyin; Jiang, Da; Lu, Ping; Zhang, Jingdong; Yuan, Xianglin; Feng, Jifeng; Yang, Shujun; Yue, Wenbin; Zhao, Lin; Xu, Yunhua; Luo, Jinhua; Shen, Lin

doi:10.1016/j.xinn.2022.100239

Cited by 3 publications

(3 citation statements)

References 48 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a randomized phase II clinical study, icotinib plus radiotherapy was compared with radiotherapy alone in older ESCC patients with unresectable tumors: icotinib plus radiotherapy improved the median overall survival compared with radiotherapy alone [64]. Lu et al recently reported the results of a randomized phase II clinical study evaluating the effect of adding cetuximab to paclitaxel-cisplatin chemotherapy compared with chemotherapy alone in ESCC patients with metastatic disease not previously treated; in the whole population of treated ESCC patients, the mPFS was 5.7 months for cetuximab + chemotherapy compared with 4.2 months for chemotherapy alone; in the selected population of ESCC patients with EGFR amplification, the mPFS was 5.45 months for cetuximab + chemotherapy compared with 2.99 months for chemotherapy alone [66]. However, the overall survival was not significantly different in the two treatment arms in the whole ESCC population (11.5 months in the chemotherapy + cetuximab group compared with 10.5 months in the chemotherapy alone group); however, a clear trend of overall survival was observed considering only the EGFR-amplified patients (17.1 months versus 6 months in the cetuximab + chemotherapy and chemotherapy alone, respectively) [66].…”

Section: Egfrmentioning

confidence: 99%

The Molecular Characterization of Genetic Abnormalities in Esophageal Squamous Cell Carcinoma May Foster the Development of Targeted Therapies

Testa

Castelli

2023

Current Oncology

View full text Add to dashboard Cite

Esophageal cancer is among the most common tumors in the world and is associated with poor outcomes, with a 5-year survival rate of about 10–20%. Two main histological subtypes are observed: esophageal squamous cell carcinoma (ESCC), more frequent among Asian populations, and esophageal adenocarcinoma (EAC), the predominant type in Western populations. The development of molecular analysis techniques has led to the definition of the molecular alterations observed in ESCC, consistently differing from those observed in EAC. The genetic alterations observed are complex and heterogeneous and involve gene mutations, gene deletions and gene amplifications. However, despite the consistent progress in the definition of the molecular basis of ESCC, precision oncology for these patients is still virtually absent. The recent identification of molecular subtypes of ESCC with clinical relevance may foster the development of new therapeutic strategies. It is estimated that about 40% of the genetic alterations observed in ESCC are actionable. Furthermore, the recent introduction of solid tumor immunotherapy with immune checkpoint inhibitors (ICIs) showed that a minority of ESCC patients are responsive, and the administration of ICIs, in combination with standard chemotherapy, significantly improves overall survival over chemotherapy in ESCC patients with advanced disease.

show abstract

Section: Egfrmentioning

confidence: 99%

The Molecular Characterization of Genetic Abnormalities in Esophageal Squamous Cell Carcinoma May Foster the Development of Targeted Therapies

Testa

Castelli

2023

Current Oncology

View full text Add to dashboard Cite

show abstract

“…Moreover, another randomized, multicentre phase II trial used cetuximab in combination with PTX‐cisplatin chemotherapy (CTP) as a first‐line treatment to achieve effective targeted therapy in patients with metastatic ESCC, which significantly prolonged the PFS and mOS of patients and achieved a manageable safety profile. [ 188 ] Another anti‐EGFR monoclonal antibody, nimotuzumab, was administered in combination with chemotherapy in the treatment of locally advanced or metastatic EC and showed a better short‐term effect without accumulation of toxicity and was well tolerated. [ 189 ] EGFR tyrosine kinase inhibitors, such as icotinib and gefitinib, also exhibited significant efficacy in the treatment of patients with EGFR‐overexpressing ESCC.…”

Section: Oesophageal Squamous Carcinoma Therapymentioning

confidence: 99%

“…Positive rates Agents Outcomes EGFR pathways 97%, [62] 49.2% [63] Cetuximab mOS: 9.5 months; [ 187] mOS: 11.5 months. [ 188] Nimotuzumab Disease control rate: 81%. [ 189] mPFS: 13.9 months; mOS: 9 months.…”

Section: Targetsmentioning

confidence: 99%

Advances in the Theranostics of Oesophageal Squamous Carcinoma

Cheng

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

Oesophageal squamous carcinoma (ESCC) is one of the most lethal human malignancies, and it is a more aggressive form of oesophageal cancer (EC) that comprises over 90% of all EC cases in China compared with oesophageal adenocarcinoma (EAC). The high mortality of ESCC is attributed to the late‐stage diagnosis, chemoradiotherapy resistance, and lack of appropriate therapeutic targets and corresponding therapeutic formulations. Recently, emerging clinical and translational investigations have involved genome analyses, diagnostic biomarkers, and targeted therapy for ESCC, and these studies provide a new horizon for improving the clinical outcomes of patients with ESCC. Here, the latest research advances in the theranostics of ESCC are reviewed and the unique features of ESCC (including differences from EAC, genomic alterations, and microbe infections), tissue and circulating biomarkers, chemoradiotherapy resistance, clinical targeted therapy for ESCC, identification of novel therapeutic targets, and designation of nanotherapeutic systems for ESCC are particularly focused on. Finally, the perspectives for future clinical and translational theranostic research of ESCC are discussed and the obstacles that must be overcome in ESCC theranostics are described.

show abstract

Meta-analysis of studies on the effectiveness of adding anti-PD1 antibodies to the first-line chemotherapy in advanced esophageal cancer

Fedyanin¹,

Tryakin²,

Rays³

et al. 2023

Malignant Tumours

View full text Add to dashboard Cite

Introduction: The results of six randomized control trials have been published by 2022, which evaluated the efficacy of adding PD-1 inhibitors to the first-line chemotherapy in patients with metastatic esophageal cancer. However, it still remains unclear which patients derive the most clinical benefit from combined therapy. Therefore, it is necessary to evaluate the efficacy of the combination of anti-PD1 treatment with chemotherapy in different patient subgroups.Materials and methods: We conducted a meta-analysis of randomized controlled trials in patients with stage IV esophageal cancer who received anti-PD1 drugs with different chemotherapeutic regimens in the first-line setting to select patients who benefit the most from the combined therapy.Results: Six randomized trials were included in the analysis for a total of 3,813 patients. Patients who received combination therapy had significantly longer OS (HR = 0.69, 95% CI: 0.63-0.75; p < 0.001), PFS (HR = 0.62, 95% CI: 0.56-0.69; p < 0.001), and better ORR (OR = 2.12, 95% CI: 1.85-2.42; p < 0.001) than those who received chemotherapy alone. Subgroup analyses showed no benefit of adding PD1-inhibitors to chemotherapy in patients with PD-L1 CPS <1 in terms of OS (HR = 0.58, 95 % CI: 0.31-1.1; p = 0.1) as well as in never-smokers (HR = 0.9, 95% CI: 0.67-1.23; p = 0.52).Conclusions: The addition of PD-1 inhibitors to the first-line chemotherapy in patients with metastatic esophageal cancer significantly improves treatment outcomes. Our results could not strongly suggest the selected patients' cohort which would benefit the most from the combination of PD-1 inhibitors and chemotherapy use.

show abstract

Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial

Cited by 3 publications

References 48 publications

The Molecular Characterization of Genetic Abnormalities in Esophageal Squamous Cell Carcinoma May Foster the Development of Targeted Therapies

The Molecular Characterization of Genetic Abnormalities in Esophageal Squamous Cell Carcinoma May Foster the Development of Targeted Therapies

Advances in the Theranostics of Oesophageal Squamous Carcinoma

Meta-analysis of studies on the effectiveness of adding anti-PD1 antibodies to the first-line chemotherapy in advanced esophageal cancer

Contact Info

Product

Resources

About